Renin-Angiotensin-Aldosterone System Blockade (RAASB) After Acute Kidney Injury: The Controversy Thickens on If and When to Discontinue RAASB

Abstract

Unquestionably, there is a common consensus regarding cardiorenal protection with renin-angiotensinaldosterone system blockade (RAASB) in both diabetic and nondiabetic chronic kidney disease (CKD). Nevertheless, there remain conflicting retrospective reports regarding renal and cardiovascular mortality outcomes following discontinuation of RAASB in advanced CKD. We present an editorial on a recent article discussing renal and mortality outcomes among hospitalized veterans who were started back on RAASB versus those who were not started back on RAASB. The controversy surrounding this topic thickens as the analysis unfolds.Categories: Internal Medicine, Nephrology Keywords: late onset renal failure from angiotensin blockade (lorffab), angiotensin receptor blocker (arb), ace inhibitor (acei), chronic kidney disease (ckd), acute kidney injury (aki), renin-angiotensin-aldosterone system blockade (raasb)